Your browser doesn't support javascript.
loading
A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models.
Singh, Dharaminder; Deosarkar, Sudhir P; Cadogan, Elaine; Flemington, Vikki; Bray, Alysha; Zhang, Jingwen; Reiserer, Ronald S; Schaffer, David K; Gerken, Gregory B; Britt, Clayton M; Werner, Erik M; Gibbons, Francis D; Kostrzewski, Tomasz; Chambers, Christopher E; Davies, Emma J; Montoya, Antonio Ramos; Fok, Jacqueline H L; Hughes, David; Fabre, Kristin; Wagoner, Matthew P; Wikswo, John P; Scott, Clay W.
Afiliação
  • Singh D; CN Bio Innovations Limited, Cambridge, United Kingdom.
  • Deosarkar SP; Oncology Safety, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States of America.
  • Cadogan E; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Flemington V; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Bray A; CN Bio Innovations Limited, Cambridge, United Kingdom.
  • Zhang J; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts, United States of America.
  • Reiserer RS; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America.
  • Schaffer DK; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America.
  • Gerken GB; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America.
  • Britt CM; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America.
  • Werner EM; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America.
  • Gibbons FD; DMPK, Oncology R&D, AstraZeneca, Boston, Massachusetts, United States of America.
  • Kostrzewski T; CN Bio Innovations Limited, Cambridge, United Kingdom.
  • Chambers CE; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Davies EJ; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Montoya AR; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Fok JHL; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Hughes D; CN Bio Innovations Limited, Cambridge, United Kingdom.
  • Fabre K; MPS Center of Excellence, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States of America.
  • Wagoner MP; Oncology Safety, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States of America.
  • Wikswo JP; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America.
  • Scott CW; Departments of Biomedical Engineering and Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, United States of America.
PLoS Biol ; 20(5): e3001624, 2022 05.
Article em En | MEDLINE | ID: mdl-35617197
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Técnicas de Cultura de Células / Microfluídica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Técnicas de Cultura de Células / Microfluídica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article